Perceived challenges and attitudes to regimen and product selection from Italian haemophilia treaters: The 2013 AICE survey

M. Franchini, A. Coppola, A. Rocino, E. Zanon, M. Morfini, Arianna Accorsi, Anna Brigida Aru, Chiara Biasoli, Isabella Cantori, Giancarlo Castaman, Simone Cesaro, Carlo Ciabatta, Raimondo De Cristofaro, Grazia Delios, Giovanni Di Minno, Marco D'Incà, Alfredo Dragani, Cosimo Pietro Ettorre, Fabio Gagliano, Gabriella GambaGiorgio Gandini, Paola Giordano, Gaetano Giuffrida, Paolo Gresele, Caterina Latella, Matteo Luciani, Maurizio Margaglione, Marco Marietta, Maria Gabriella Mazzucconi, Maria Messina, Angelo Claudio Molinari, Lucia Dora Notarangelo, Emily Oliovecchio, Flora Peyvandi, Gavino Piseddu, Gina Rossetti, Vincenza Rossi, Elena Santagostino, Mario Schiavoni, Piercarla Schinco, Maria Luisa Serino, Annarita Tagliaferri, Sophie Testa

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

Despite great advances in haemophilia care in the last 20 years, a number of questions on haemophilia therapy remain unanswered. These debated issues primarily involve the choice of the product type (plasma-derived vs. recombinant) for patients with different characteristics: specifically, if they were infected by blood-borne virus infections, and if they bear high or low risk of inhibitor development. In addition, the most appropriate treatment regimen in non-inhibitor and inhibitor patients compel physicians operating at the haemophilia treatment centres (HTCs) to take important therapeutic decisions, which are often based on their personal clinical experience rather than on evidence-based recommendations from published literature data. To know the opinion on the most controversial aspects in haemophilia care of Italian expert physicians, who are responsible for common clinical practice and therapeutic decisions, we have conducted a survey among the Directors of HTCs affiliated to the Italian Association of Haemophilia Centres (AICE). A questionnaire, consisting of 19 questions covering the most important topics related to haemophilia treatment, was sent to the Directors of all 52 Italian HTCs. Forty Directors out of 52 (76.9%) responded, accounting for the large majority of HTCs affiliated to the AICE throughout Italy. The results of this survey provide for the first time a picture of the attitudes towards clotting factor concentrate use and product selection of clinicians working at Italian HTCs.

Original languageEnglish
JournalHaemophilia
Volume20
Issue number2
DOIs
Publication statusPublished - 2014

Fingerprint

Hemophilia A
Therapeutics
Surveys and Questionnaires
Physicians
Blood Coagulation Factors
Virus Diseases
Italy

Keywords

  • Factor concentrates
  • Haemophilia treatment
  • Inhibitor
  • Prophylaxis
  • Survey
  • Viral safety

ASJC Scopus subject areas

  • Hematology
  • Genetics(clinical)

Cite this

Perceived challenges and attitudes to regimen and product selection from Italian haemophilia treaters : The 2013 AICE survey. / Franchini, M.; Coppola, A.; Rocino, A.; Zanon, E.; Morfini, M.; Accorsi, Arianna; Aru, Anna Brigida; Biasoli, Chiara; Cantori, Isabella; Castaman, Giancarlo; Cesaro, Simone; Ciabatta, Carlo; De Cristofaro, Raimondo; Delios, Grazia; Di Minno, Giovanni; D'Incà, Marco; Dragani, Alfredo; Ettorre, Cosimo Pietro; Gagliano, Fabio; Gamba, Gabriella; Gandini, Giorgio; Giordano, Paola; Giuffrida, Gaetano; Gresele, Paolo; Latella, Caterina; Luciani, Matteo; Margaglione, Maurizio; Marietta, Marco; Gabriella Mazzucconi, Maria; Messina, Maria; Molinari, Angelo Claudio; Notarangelo, Lucia Dora; Oliovecchio, Emily; Peyvandi, Flora; Piseddu, Gavino; Rossetti, Gina; Rossi, Vincenza; Santagostino, Elena; Schiavoni, Mario; Schinco, Piercarla; Serino, Maria Luisa; Tagliaferri, Annarita; Testa, Sophie.

In: Haemophilia, Vol. 20, No. 2, 2014.

Research output: Contribution to journalArticle

Franchini, M, Coppola, A, Rocino, A, Zanon, E, Morfini, M, Accorsi, A, Aru, AB, Biasoli, C, Cantori, I, Castaman, G, Cesaro, S, Ciabatta, C, De Cristofaro, R, Delios, G, Di Minno, G, D'Incà, M, Dragani, A, Ettorre, CP, Gagliano, F, Gamba, G, Gandini, G, Giordano, P, Giuffrida, G, Gresele, P, Latella, C, Luciani, M, Margaglione, M, Marietta, M, Gabriella Mazzucconi, M, Messina, M, Molinari, AC, Notarangelo, LD, Oliovecchio, E, Peyvandi, F, Piseddu, G, Rossetti, G, Rossi, V, Santagostino, E, Schiavoni, M, Schinco, P, Serino, ML, Tagliaferri, A & Testa, S 2014, 'Perceived challenges and attitudes to regimen and product selection from Italian haemophilia treaters: The 2013 AICE survey', Haemophilia, vol. 20, no. 2. https://doi.org/10.1111/hae.12334
Franchini, M. ; Coppola, A. ; Rocino, A. ; Zanon, E. ; Morfini, M. ; Accorsi, Arianna ; Aru, Anna Brigida ; Biasoli, Chiara ; Cantori, Isabella ; Castaman, Giancarlo ; Cesaro, Simone ; Ciabatta, Carlo ; De Cristofaro, Raimondo ; Delios, Grazia ; Di Minno, Giovanni ; D'Incà, Marco ; Dragani, Alfredo ; Ettorre, Cosimo Pietro ; Gagliano, Fabio ; Gamba, Gabriella ; Gandini, Giorgio ; Giordano, Paola ; Giuffrida, Gaetano ; Gresele, Paolo ; Latella, Caterina ; Luciani, Matteo ; Margaglione, Maurizio ; Marietta, Marco ; Gabriella Mazzucconi, Maria ; Messina, Maria ; Molinari, Angelo Claudio ; Notarangelo, Lucia Dora ; Oliovecchio, Emily ; Peyvandi, Flora ; Piseddu, Gavino ; Rossetti, Gina ; Rossi, Vincenza ; Santagostino, Elena ; Schiavoni, Mario ; Schinco, Piercarla ; Serino, Maria Luisa ; Tagliaferri, Annarita ; Testa, Sophie. / Perceived challenges and attitudes to regimen and product selection from Italian haemophilia treaters : The 2013 AICE survey. In: Haemophilia. 2014 ; Vol. 20, No. 2.
@article{472b761a50f34e60b07e7adddd711a6a,
title = "Perceived challenges and attitudes to regimen and product selection from Italian haemophilia treaters: The 2013 AICE survey",
abstract = "Despite great advances in haemophilia care in the last 20 years, a number of questions on haemophilia therapy remain unanswered. These debated issues primarily involve the choice of the product type (plasma-derived vs. recombinant) for patients with different characteristics: specifically, if they were infected by blood-borne virus infections, and if they bear high or low risk of inhibitor development. In addition, the most appropriate treatment regimen in non-inhibitor and inhibitor patients compel physicians operating at the haemophilia treatment centres (HTCs) to take important therapeutic decisions, which are often based on their personal clinical experience rather than on evidence-based recommendations from published literature data. To know the opinion on the most controversial aspects in haemophilia care of Italian expert physicians, who are responsible for common clinical practice and therapeutic decisions, we have conducted a survey among the Directors of HTCs affiliated to the Italian Association of Haemophilia Centres (AICE). A questionnaire, consisting of 19 questions covering the most important topics related to haemophilia treatment, was sent to the Directors of all 52 Italian HTCs. Forty Directors out of 52 (76.9{\%}) responded, accounting for the large majority of HTCs affiliated to the AICE throughout Italy. The results of this survey provide for the first time a picture of the attitudes towards clotting factor concentrate use and product selection of clinicians working at Italian HTCs.",
keywords = "Factor concentrates, Haemophilia treatment, Inhibitor, Prophylaxis, Survey, Viral safety",
author = "M. Franchini and A. Coppola and A. Rocino and E. Zanon and M. Morfini and Arianna Accorsi and Aru, {Anna Brigida} and Chiara Biasoli and Isabella Cantori and Giancarlo Castaman and Simone Cesaro and Carlo Ciabatta and {De Cristofaro}, Raimondo and Grazia Delios and {Di Minno}, Giovanni and Marco D'Inc{\`a} and Alfredo Dragani and Ettorre, {Cosimo Pietro} and Fabio Gagliano and Gabriella Gamba and Giorgio Gandini and Paola Giordano and Gaetano Giuffrida and Paolo Gresele and Caterina Latella and Matteo Luciani and Maurizio Margaglione and Marco Marietta and {Gabriella Mazzucconi}, Maria and Maria Messina and Molinari, {Angelo Claudio} and Notarangelo, {Lucia Dora} and Emily Oliovecchio and Flora Peyvandi and Gavino Piseddu and Gina Rossetti and Vincenza Rossi and Elena Santagostino and Mario Schiavoni and Piercarla Schinco and Serino, {Maria Luisa} and Annarita Tagliaferri and Sophie Testa",
year = "2014",
doi = "10.1111/hae.12334",
language = "English",
volume = "20",
journal = "Haemophilia",
issn = "1351-8216",
publisher = "Wiley-Blackwell Publishing Ltd",
number = "2",

}

TY - JOUR

T1 - Perceived challenges and attitudes to regimen and product selection from Italian haemophilia treaters

T2 - The 2013 AICE survey

AU - Franchini, M.

AU - Coppola, A.

AU - Rocino, A.

AU - Zanon, E.

AU - Morfini, M.

AU - Accorsi, Arianna

AU - Aru, Anna Brigida

AU - Biasoli, Chiara

AU - Cantori, Isabella

AU - Castaman, Giancarlo

AU - Cesaro, Simone

AU - Ciabatta, Carlo

AU - De Cristofaro, Raimondo

AU - Delios, Grazia

AU - Di Minno, Giovanni

AU - D'Incà, Marco

AU - Dragani, Alfredo

AU - Ettorre, Cosimo Pietro

AU - Gagliano, Fabio

AU - Gamba, Gabriella

AU - Gandini, Giorgio

AU - Giordano, Paola

AU - Giuffrida, Gaetano

AU - Gresele, Paolo

AU - Latella, Caterina

AU - Luciani, Matteo

AU - Margaglione, Maurizio

AU - Marietta, Marco

AU - Gabriella Mazzucconi, Maria

AU - Messina, Maria

AU - Molinari, Angelo Claudio

AU - Notarangelo, Lucia Dora

AU - Oliovecchio, Emily

AU - Peyvandi, Flora

AU - Piseddu, Gavino

AU - Rossetti, Gina

AU - Rossi, Vincenza

AU - Santagostino, Elena

AU - Schiavoni, Mario

AU - Schinco, Piercarla

AU - Serino, Maria Luisa

AU - Tagliaferri, Annarita

AU - Testa, Sophie

PY - 2014

Y1 - 2014

N2 - Despite great advances in haemophilia care in the last 20 years, a number of questions on haemophilia therapy remain unanswered. These debated issues primarily involve the choice of the product type (plasma-derived vs. recombinant) for patients with different characteristics: specifically, if they were infected by blood-borne virus infections, and if they bear high or low risk of inhibitor development. In addition, the most appropriate treatment regimen in non-inhibitor and inhibitor patients compel physicians operating at the haemophilia treatment centres (HTCs) to take important therapeutic decisions, which are often based on their personal clinical experience rather than on evidence-based recommendations from published literature data. To know the opinion on the most controversial aspects in haemophilia care of Italian expert physicians, who are responsible for common clinical practice and therapeutic decisions, we have conducted a survey among the Directors of HTCs affiliated to the Italian Association of Haemophilia Centres (AICE). A questionnaire, consisting of 19 questions covering the most important topics related to haemophilia treatment, was sent to the Directors of all 52 Italian HTCs. Forty Directors out of 52 (76.9%) responded, accounting for the large majority of HTCs affiliated to the AICE throughout Italy. The results of this survey provide for the first time a picture of the attitudes towards clotting factor concentrate use and product selection of clinicians working at Italian HTCs.

AB - Despite great advances in haemophilia care in the last 20 years, a number of questions on haemophilia therapy remain unanswered. These debated issues primarily involve the choice of the product type (plasma-derived vs. recombinant) for patients with different characteristics: specifically, if they were infected by blood-borne virus infections, and if they bear high or low risk of inhibitor development. In addition, the most appropriate treatment regimen in non-inhibitor and inhibitor patients compel physicians operating at the haemophilia treatment centres (HTCs) to take important therapeutic decisions, which are often based on their personal clinical experience rather than on evidence-based recommendations from published literature data. To know the opinion on the most controversial aspects in haemophilia care of Italian expert physicians, who are responsible for common clinical practice and therapeutic decisions, we have conducted a survey among the Directors of HTCs affiliated to the Italian Association of Haemophilia Centres (AICE). A questionnaire, consisting of 19 questions covering the most important topics related to haemophilia treatment, was sent to the Directors of all 52 Italian HTCs. Forty Directors out of 52 (76.9%) responded, accounting for the large majority of HTCs affiliated to the AICE throughout Italy. The results of this survey provide for the first time a picture of the attitudes towards clotting factor concentrate use and product selection of clinicians working at Italian HTCs.

KW - Factor concentrates

KW - Haemophilia treatment

KW - Inhibitor

KW - Prophylaxis

KW - Survey

KW - Viral safety

UR - http://www.scopus.com/inward/record.url?scp=84894026319&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84894026319&partnerID=8YFLogxK

U2 - 10.1111/hae.12334

DO - 10.1111/hae.12334

M3 - Article

C2 - 24533954

AN - SCOPUS:84894026319

VL - 20

JO - Haemophilia

JF - Haemophilia

SN - 1351-8216

IS - 2

ER -